Research progress on the relationship between urinary tract microbiome and bladder cancer_West China Medical Journal

Authors：

LI Dengxiong , BAI Yunjin , TANG Yin ,  HAN Ping

Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

HAN Ping, Email: hanpingwch@163.com

Keywords：

Microorganisms; Bladder cancer; Bacillus Calmette-Guerin vaccine

DOI：

10.7507/1002-0179.201908051

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Bladder cancer is a common malignant tumor of the urinary system. The incidence and mortality of bladder cancer in China have been at a high level. In the past, people generally believed that the bladder was a sterile environment, but it has been found that there are symbiotic microorganisms in the bladder. In addition, microorganisms and their metabolites in urine may be involved in the occurrence and development of various urinary system diseases such as bladder cancer. At the same time, microorganisms and their component products such as Bacillus Calmette-Guerin vaccine play an important role in the treatment of bladder cancer. This article reviews the research progress of urinary tract microorganisms and the occurrence, development and treatment of bladder cancer, and aims to provide new ideas for the early diagnosis and treatment, prevention and prognosis evaluation of bladder cancer.

Citation： LI Dengxiong, BAI Yunjin, TANG Yin, HAN Ping. Research progress on the relationship between urinary tract microbiome and bladder cancer. West China Medical Journal, 2021, 36(7): 986-989. doi: 10.7507/1002-0179.201908051 Copy

1.	郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析. 中华肿瘤杂志, 2019, 41(1): 19-28.
2.	Bajic P, Van Kuiken ME, Burge BK, et al. Male bladder microbiome relates to lower urinary tract symptoms. Eur Urol Focus, 2020, 6(2): 376-382.
3.	Janssen DAW. The microbiome: another dimension in the pathophysiology of urogenital disease. Eur Urol, 2019, 75(4): 647-648.
4.	Markowski MC, Boorjian SA, Burton JP, et al. The microbiome and genitourinary cancer: a collaborative review. Eur Urol, 2019, 75(4): 637-646.
5.	曾嘉荣. 泌尿道菌群在膀胱癌诊断以及预后判断中的价值研究. 广州: 南方医科大学, 2020: 1-69.
6.	Lotan Y, Black PC, Caba L, et al. Optimal trial design for studying urinary markers in bladder cancer: a collaborative review. Eur Urol Oncol, 2018, 1(3): 223-230.
7.	Cai S, Kandasamy M, Rahmat JN, et al. Lactobacillus rhamnosus GG activation of dendritic cells and neutrophils depends on the dose and time of exposure. J Immunol Res, 2016, 2016: 7402760.
8.	van Puffelen JH, Keating ST, Oosterwijk E, et al. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nat Rev Urol, 2020, 17(9): 513-525.
9.	Helmink BA, Khan MAW, Hermann A, et al. The microbiome, cancer, and cancer therapy. Nat Med, 2019, 25(3): 377-388.
10.	Mbanefo EC, Fu CL, Ho CP, et al. Interleukin-4 signaling plays a major role in urogenital schistosomiasis-associated bladder pathogenesis. Infect Immun, 2020, 88(3): e00669-19.
11.	Dematei A, Fernandes R, Soares R, et al. Angiogenesis in Schistosoma haematobium-associated urinary bladder cancer. APMIS, 2017, 125(12): 1056-1062.
12.	Adebayo AS, Suryavanshi MV, Bhute S, et al. The microbiome in urogenital schistosomiasis and induced bladder pathologies. PLoS Negl Trop Dis, 2017, 11(8): e0005826.
13.	Mostafa MH, Sheweita SA, O’Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev, 1999, 12(1): 97-111.
14.	Adebayo AS, Mundhe SD, Awobode HO, et al. Metabolite profiling for biomarkers in Schistosoma haematobium infection and associated bladder pathologies. PLoS Negl Trop Dis, 2018, 12(4): e0006452.
15.	Xu W, Yang L, Lee P, et al. Mini-review: perspective of the microbiome in the pathogenesis of urothelial carcinoma. Am J Clin Exp Urol, 2014, 2(1): 57-61.
16.	Bučević Popović V, Šitum M, Chow CT, et al. The urinary microbiome associated with bladder cancer. Sci Rep, 2018, 8(1): 12157.
17.	Chipollini J, Wright JR, Nwanosike H, et al. Characterization of urinary microbiome in patients with bladder cancer: results from a single-institution, feasibility study. Urol Oncol, 2020, 38(7): 615-621.
18.	Mansour B, Monyók Á, Makra N, et al. Bladder cancer-related microbiota: examining differences in urine and tissue samples. Sci Rep, 2020, 10(1): 11042.
19.	Pederzoli F, Ferrarese R, Amato V, et al. Sex-specific alterations in the urinary and tissue microbiome in therapy-naïve urothelial bladder cancer patients. Eur Urol Oncol, 2020, 3(6): 784-788.
20.	张桂豪, 陈嘉炜, 陈杨, 等. 男性非肌层浸润性膀胱癌患者的尿液菌群特征. 中华泌尿外科杂志, 2018, 39(9): 685-689.
21.	Lughezzani G, Sun M, Shariat SF, et al. A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. Cancer, 2011, 117(1): 103-109.
22.	Wu P, Zhang G, Zhao J, et al. Profiling the urinary microbiota in male patients with bladder cancer in China. Front Cell Infect Microbiol, 2018, 8: 167.
23.	Oresta B, Braga D, Lazzeri M, et al. The microbiome of catheter collected urine in males with bladder cancer according to disease stage. J Urol, 2021, 205(1): 86-93.
24.	McConnell MJ, Actis L, Pachón J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev, 2013, 37(2): 130-155.
25.	Alfano M, Canducci F, Nebuloni M, et al. The interplay of extracellular matrix and microbiome in urothelial bladder cancer. Nat Rev Urol, 2016, 13(2): 77-90.
26.	Wolfe AJ, Toh E, Shibata N, et al. Evidence of uncultivated bacteria in the adult female bladder. J Clin Microbiol, 2012, 50(4): 1376-1383.
27.	Fujita N, Hatakeyama S, Momota M, et al. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer. Urol Oncol, 2020, 38(8): 684. e17-684. e24.
28.	Sweis RF, Golan S, Barashi N, et al. The commensal urinary microbiome as a predictor of response to Bacillus Calmette-Guerin (BCG) immunotherapy in non-muscle invasive bladder cancer. J Clin Oncol, 2019, 13(79): 423.
29.	Seow SW, Rahmat JN, Bay BH, et al. Expression of chemokine/cytokine genes and immune cell recruitment following the instillation of Mycobacterium bovis, bacillus Calmette-Guérin or Lactobacillus rhamnosus strain GG in the healthy murine bladder. Immunology, 2008, 124(3): 419-427.
30.	Seow SW, Cai S, Rahmat JN, et al. Lactobacillus rhamnosus GG induces tumor regression in mice bearing orthotopic bladder tumors. Cancer Sci, 2010, 101(3): 751-758.

1. 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析. 中华肿瘤杂志, 2019, 41(1): 19-28.
2. Bajic P, Van Kuiken ME, Burge BK, et al. Male bladder microbiome relates to lower urinary tract symptoms. Eur Urol Focus, 2020, 6(2): 376-382.
3. Janssen DAW. The microbiome: another dimension in the pathophysiology of urogenital disease. Eur Urol, 2019, 75(4): 647-648.
4. Markowski MC, Boorjian SA, Burton JP, et al. The microbiome and genitourinary cancer: a collaborative review. Eur Urol, 2019, 75(4): 637-646.
5. 曾嘉荣. 泌尿道菌群在膀胱癌诊断以及预后判断中的价值研究. 广州: 南方医科大学, 2020: 1-69.
6. Lotan Y, Black PC, Caba L, et al. Optimal trial design for studying urinary markers in bladder cancer: a collaborative review. Eur Urol Oncol, 2018, 1(3): 223-230.
7. Cai S, Kandasamy M, Rahmat JN, et al. Lactobacillus rhamnosus GG activation of dendritic cells and neutrophils depends on the dose and time of exposure. J Immunol Res, 2016, 2016: 7402760.
8. van Puffelen JH, Keating ST, Oosterwijk E, et al. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nat Rev Urol, 2020, 17(9): 513-525.
9. Helmink BA, Khan MAW, Hermann A, et al. The microbiome, cancer, and cancer therapy. Nat Med, 2019, 25(3): 377-388.
10. Mbanefo EC, Fu CL, Ho CP, et al. Interleukin-4 signaling plays a major role in urogenital schistosomiasis-associated bladder pathogenesis. Infect Immun, 2020, 88(3): e00669-19.
11. Dematei A, Fernandes R, Soares R, et al. Angiogenesis in Schistosoma haematobium-associated urinary bladder cancer. APMIS, 2017, 125(12): 1056-1062.
12. Adebayo AS, Suryavanshi MV, Bhute S, et al. The microbiome in urogenital schistosomiasis and induced bladder pathologies. PLoS Negl Trop Dis, 2017, 11(8): e0005826.
13. Mostafa MH, Sheweita SA, O’Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev, 1999, 12(1): 97-111.
14. Adebayo AS, Mundhe SD, Awobode HO, et al. Metabolite profiling for biomarkers in Schistosoma haematobium infection and associated bladder pathologies. PLoS Negl Trop Dis, 2018, 12(4): e0006452.
15. Xu W, Yang L, Lee P, et al. Mini-review: perspective of the microbiome in the pathogenesis of urothelial carcinoma. Am J Clin Exp Urol, 2014, 2(1): 57-61.
16. Bučević Popović V, Šitum M, Chow CT, et al. The urinary microbiome associated with bladder cancer. Sci Rep, 2018, 8(1): 12157.
17. Chipollini J, Wright JR, Nwanosike H, et al. Characterization of urinary microbiome in patients with bladder cancer: results from a single-institution, feasibility study. Urol Oncol, 2020, 38(7): 615-621.
18. Mansour B, Monyók Á, Makra N, et al. Bladder cancer-related microbiota: examining differences in urine and tissue samples. Sci Rep, 2020, 10(1): 11042.
19. Pederzoli F, Ferrarese R, Amato V, et al. Sex-specific alterations in the urinary and tissue microbiome in therapy-naïve urothelial bladder cancer patients. Eur Urol Oncol, 2020, 3(6): 784-788.
20. 张桂豪, 陈嘉炜, 陈杨, 等. 男性非肌层浸润性膀胱癌患者的尿液菌群特征. 中华泌尿外科杂志, 2018, 39(9): 685-689.
21. Lughezzani G, Sun M, Shariat SF, et al. A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. Cancer, 2011, 117(1): 103-109.
22. Wu P, Zhang G, Zhao J, et al. Profiling the urinary microbiota in male patients with bladder cancer in China. Front Cell Infect Microbiol, 2018, 8: 167.
23. Oresta B, Braga D, Lazzeri M, et al. The microbiome of catheter collected urine in males with bladder cancer according to disease stage. J Urol, 2021, 205(1): 86-93.
24. McConnell MJ, Actis L, Pachón J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev, 2013, 37(2): 130-155.
25. Alfano M, Canducci F, Nebuloni M, et al. The interplay of extracellular matrix and microbiome in urothelial bladder cancer. Nat Rev Urol, 2016, 13(2): 77-90.
26. Wolfe AJ, Toh E, Shibata N, et al. Evidence of uncultivated bacteria in the adult female bladder. J Clin Microbiol, 2012, 50(4): 1376-1383.
27. Fujita N, Hatakeyama S, Momota M, et al. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer. Urol Oncol, 2020, 38(8): 684. e17-684. e24.
28. Sweis RF, Golan S, Barashi N, et al. The commensal urinary microbiome as a predictor of response to Bacillus Calmette-Guerin (BCG) immunotherapy in non-muscle invasive bladder cancer. J Clin Oncol, 2019, 13(79): 423.
29. Seow SW, Rahmat JN, Bay BH, et al. Expression of chemokine/cytokine genes and immune cell recruitment following the instillation of Mycobacterium bovis, bacillus Calmette-Guérin or Lactobacillus rhamnosus strain GG in the healthy murine bladder. Immunology, 2008, 124(3): 419-427.
30. Seow SW, Cai S, Rahmat JN, et al. Lactobacillus rhamnosus GG induces tumor regression in mice bearing orthotopic bladder tumors. Cancer Sci, 2010, 101(3): 751-758.

Previous Article
Clinical research progress of peroral endoscopic non-full-thickness therapy for gastroesophageal reflux disease
Next Article
Periodontitis and benign prostatic hyperplasia and prostatitis

West China Medical Journal

Research progress on the relationship between urinary tract microbiome and bladder cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content